Verrica Pharmaceuticals Inc. (VRCA) Stock Price & Analysis
Verrica Pharmaceuticals Inc. (VRCA) rose 2.17% to USD 6.12 as of June 10, 2026 at 07:20 UTC, according to Nexqual real-time market data.
VRCA last closed at USD 5.99; the session ranged USD 5.94–6.38 on volume of 33,040 shares. Market capitalization is $105.13M, with a 52-week range of USD 3.28–9.82 (NCM). Source: Nexqual, June 10, 2026 at 07:20 UTC.
Key Statistics (as of June 10, 2026 at 07:20 UTC)
| Price | USD 6.12 |
|---|---|
| Change | ▲ 2.17% (up) |
| Previous Close | USD 5.99 |
| Open | USD 6.03 |
| Day Range | USD 5.94 – 6.38 |
| 52-Week Range | USD 3.28 – 9.82 |
| Volume | 33,040 shares |
| Market Cap | $105.13M |
| Exchange | NCM |
Technical Analysis (VRCA)
Nexqual's technical model rates VRCA "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.36 (neutral) |
| vs SMA50 | Below (USD 6.23) |
| MACD | -0.15 (negative) |
Analyst Ratings (VRCA)
Wall Street analysts rate VRCA "None" based on 5 analysts, with a mean price target of USD 15.54 (range USD 10–20), per Nexqual as of June 10, 2026 at 07:20 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 15.54 |
| High Target | USD 20 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (VRCA)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.45 |
| Revenue Estimate | $5.90M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.51 vs est -0.64 ▲ beat |
| 2025-09-30 | USD 0.13 vs est -0.84 ▲ beat |
| 2025-06-30 | USD 0.25 vs est -0.83 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:20 UTC.
Financials & Fundamentals (VRCA)
| Total Revenue | $37.16M |
|---|---|
| Revenue Growth (YoY) | +46.10% |
| Gross Margin | +61.45% |
| Operating Margin | -193.41% |
| Profit Margin | -47.97% |
| Debt / Equity | 8.98 |
| Current Ratio | 2.1 |
| Total Cash | $20.60M |
| Total Debt | $1.44M |
| Free Cash Flow | $-12.16M |
Source: Nexqual, June 10, 2026 at 07:20 UTC.
Financial Health Score (VRCA)
Nexqual rates Verrica Pharmaceuticals Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:20 UTC.
| Growth | Strong — Revenue +370% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $21M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Mixed — No data |
Ownership (VRCA)
| Insider Ownership | +48.75% |
|---|---|
| Institutional Ownership | +27.87% |
| Shares Outstanding | 17.18M |
| Float | 7.90M |
| Short % of Float | +4.29% |
Source: Nexqual, June 10, 2026 at 07:20 UTC.
Leadership (VRCA)
Verrica Pharmaceuticals Inc. is led by Jayson M. Rieger (age 49), President, CEO & Director, per Nexqual as of June 10, 2026 at 07:20 UTC.
| President, CEO & Director | Jayson M. Rieger (age 49) |
|---|---|
| Interim Chief Financial Officer | John J. Kirby (age 53) |
| COO, Chief Legal Officer & Secretary | David Zawitz (age 44) |
| Executive Vice President of Technical Operations | Eugene Scavola |
Major Backers & Investors (VRCA)
Notable institutional backers of Verrica Pharmaceuticals Inc. include Caligan Partners, LP, Affinity Asset Advisors, Llc, Cannell Capital LLC, according to Nexqual as of June 10, 2026 at 07:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Caligan Partners, LP | 5.38% |
| Affinity Asset Advisors, Llc | 4.12% |
| Cannell Capital LLC | 3.99% |
| Armistice Capital, LLC | 3.02% |
| Velan Capital Investment Management LP | 2.75% |
| Boothbay Fund Management, LLC | 1.63% |
| DAFNA Capital Management, LLC | 0.89% |
| Marshall Wace LLP | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.2% |
| Geode Capital | 0.81% |
Source: Nexqual, June 10, 2026 at 07:20 UTC.
From Verrica Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- With regards to the cantharidin API, we possessed total inventories in a combination of raw cantharidin and GMP API adequate to produce over 17 million additional finished drug product applicators in the United States.
- In March 2024, YCANTH's (VP-102) active pharmaceutical ingredient, or API, received New Chemical Entity (NCE) status and a listing in the Orange Book from the FDA, providing a minimum five years of regulatory exclusivity.
- Our Product: YCANTH (VP-102) for the Treatment of Molluscum YCANTH (VP-102) is the first FDA-approved product for the treatment of molluscum and its API has been characterized as a NCE, with five years of non-patent regulatory exclusivity associated with that designation.
- Our proprietary single-use applicator allows for precise application to each lesion.
Partnerships
- Lytix BioPharma AS In August 2020, we entered into an exclusive license agreement with Lytix pursuant to which we obtained an exclusive worldwide license for certain technology of Lytix to develop VP-315 for use in all malignant and pre-malignant dermatological indications, other than metastatic melanoma and metastatic Merkel cell carcinoma.
- Torii Collaboration and License Agreement In August 2020, we entered into an option agreement with Torii for the development and commercialization of our product candidates for the treatment of molluscum and common warts in Japan, including YCANTH (VP-102), or the Option Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STRO | Sutro Biopharma, Inc. | USD 25.79 | ▼ 1.15% |
| MGTX | MeiraGTx Holdings plc | USD 9.21 | ▲ 2.33% |
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▲ 200% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.52 | ▼ 4.61% |
| ETON | Eton Pharmaceuticals, Inc. | USD 30.53 | ▲ 4.81% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:20 UTC. This page is informational and not investment advice.